BioSpace News Archive

KangaBio announced that the U.S. FDA has granted official approval for their independent R&D clinical trial application for KGX101.

Maze Therapeutics announced findings from preclinical studies demonstrating the potential of a novel APOL1 inhibitor to reverse disease manifestations of APOL1 kidney disease in a chronic APOL1 kidney disease mouse model.

Vera Therapeutics, Inc. announced the presentation of three posters – including an additional analysis of week 36 data from the Phase 2b ORIGIN study demonstrating resolution of hematuria in the majority of patients – on the Company’s product candidate atacicept in patients with immunoglobulin A nephropathy at the American Society of Nephrology Kidney Week 2023, in Philadelphia, PA.

Bayer announced new interim, real-world data on Kerendia® that complement the hyperkalemia and safety data in its pivotal trials.

Apellis Pharmaceuticals, Inc. announced data from the GALE extension study following 3 years of continuous treatment with SYFOVRE®, the first-ever FDA-approved treatment for geographic atrophy secondary to age-related macular degeneration.

TriSalus Life Sciences® Inc. presented additional Phase 1 clinical data during the late-breaker oral presentation session at the Society of Immunotherapy for Cancer 2023 Annual Meeting.

Adverum Biotechnologies, Inc. announced updated data from the OPTIC extension study of patients with wet AMD during the Retina Subspecialty Day at the American Academy of Ophthalmology 2023 Annual Meeting in San Francisco, California.

Candel Therapeutics, Inc. will present two posters during the 2023 Society for Immunotherapy of Cancer Annual Meeting in San Diego focused on the enLIGHTEN™ Discovery Platform.

Ambry Genetics, a prominent leader in clinical genomic testing and a subsidiary of REALM IDx, Inc., unveiled at the American Society of Human Genetics annual meeting results of a study published in JAMA Oncology that assessed the cumulative impact of paired DNA and RNA testing on detecting disease-causing germline genetic variants and resolution of variants of uncertain significance.

Promontory Therapeutics Inc. presented data demonstrating the molecular mechanism of its lead therapeutic candidate, PT-112, and its ability to induce immunogenic cell death in cancer cells.